Homburger advised ADC Therapeutics SA on its strategic financial restructuring

On October 8, 2026, ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company headquartered in Switzerland, announced a comprehensive strategic financial restructuring, including a USD 86.6 m private investment in public equity («PIPE») through the sale of 12.9 m common shares and pre-funded warrants to purchase 48.1 m common shares to Bain Capital Life Sciences, Redmile Group, TCGX and Nantahala Capital.

In addition, ADC Therapeutics amended its royalty financing agreement with HealthCare Royalty and its loan agreement with Blue Owl, providing, among other things, for a USD 70 m prepayment of its term loans.

Homburger advised ADC Therapeutics on the Swiss law aspects of the transaction. The Homburger team was led by Daniel Häusermann and included Estelle Piccard and Bianca Nedwed (all Corporate / M&A, Capital Markets), Benjamin Leisinger and Simone Gloor (both Financing) as well as Stefan Oesterhelt (Tax).